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Abstract 
The folate receptor has achieved great importance for use in targeted drug delivery and in 
vitro and in vivo diagnostic assays.1-2 The folate receptor (FR) is over-expressed on several 
cancer cell types and activated macrophages, but exists in relatively low abundance on the 
surface of non-cancerous tissue and non inflammatory cells. This unique attribute is the hallmark 
of folate-targeted methodologies allowing the diagnostic agent and/or drug to be ferried to the 
specific disease sites while preventing “off target” effects in normal tissues.3-4  Protein toxins, 
chemotherapeutic agents, radioimaging agents, magnetic resonance imaging (MRI) contrast 
agents liposomes with entrapped drugs, radiotherapeutic agents, and immunotherapeutic agents 
are all in current stages of development.5-6  
Although several folate-based dyes have been reported, simple and detailed synthetic and 
purification methods for these conjugates have not been reported. More importantly, several new 
photostable dyes are now commercially available that have not been tested as folate-based 
imaging agents. In tandem with the synthesis of these new folate dyes, High Performance Liquid 
Chromatography (HPLC) purification/analysis by diode array and mass spectrometry will need 
to be undertaken in order to confirm the identity of the compounds.  Thus, our objective is to 
develop a new folate-based dye and the corresponding HPLC methods for the purification and 
analysis of this conjugate. Once synthesized, we have several column types of varying lengths, 
diameters, particle sizes, (we recently acquired ~ 20 “state of the art” columns from industrial 
sources) and several HPLC’s at our disposal to analyze the compound (via retention time and 
mass spectrum).         
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 Introduction 
Folic acid 
 Folic acid (Fig-1) is water soluble vitamin, also known as vitamin B9 that is essential for 
the synthesis of the nucleotides. Folic acid is not biologically active but it forms tetrahydrofolate 
(THF) which is biologically active. Folate is important for the metabolism of homocysteine to 
maintain the level of amino acid and is necessary for the synthesis of DNA and RNA.7-8 Folate is 
required in the metabolism of the amino acids including methionine, serine, glysine, etc. If folate 
is not present in methionine metabolism, excess homocysteine build up leads to heart disease.9 It 
is very important during the cell growth and cell proliferation and is essential for the fast division 
of red blood cells and to prevent anemia.10 A lack of dietary folic acid leads to folate deficiency. 
This can result in many health problems. The most notable one is impaired DNA synthesis, 
which can lead to the development of cancer. Folic acid is especially important for pregnant 
women.11-12 
Folate receptor 
Folate receptors are present on the cell surface. They are surface glycoprotein with high 
affinity for folic acid and reduced folate which capture the folate from the extracellular liquid 
and transport to the cell.13-14 The folate receptors are present on the normal cells, however there 
is greater receptor presence on malignant cells coupled with the fact that only unique  GPI	  
(glycosylphosphatidyinositol) anchored folate receptor is the only form capable of uptake of  
falate conjugated species (reduced folate carrier is incapable of uptake of folate conjugates). This 
characteristic of malignant cells can be useful for the diagnosis of cancer. Folate receptors can be 
used for many kinds of folate conjugates like targeted drug delivery for cancer treatment and 
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folate dye conjugate for diagnosis purpose.15-16 In the case of rheumatoid arthritis, folate 
receptors on activated macrophages are able to uptake folate dye conjugate. As such, folate dye 
conjugates can be exploited for the scintigraphic imaging of the inflamed joints in arthritis.  
Folate is transported to the cell by two types of carrier systems. One is reduced folate 
carrier (RFC), which is a transmembrane protein that binds reduced folate molecules with low 
affinity. Another carrier is folate receptor (FR) also called folate receptor protein which is GPI-
anchored glycoprotein. FR binds oxidized forms of folic acid with high affinity.17-18  
Expression of Folate Receptor 
There are mainly three isoforms of folate receptors α, β and γ. FR- α is specifically 
overexpressed in most epithelial tumors like mesothelioma and ovarian carcinoma and relatively 
under expressed on normal tissues (exceptions are proximal tubules in kidney, choroid plexus, 
placenta and glandular epithelia). FR- α has very high affinity for folic acid and is considered an 
essential component in cellular accumulation of folate and folate analogues used in 
chemotherapy. While FR- α is found on cancer tissues, FR- β and FR- γ are specifically found in 
normal tissues and hematopoietic tissues.19-21  
Folate receptor pathway 
There are different mechanisms for the transportation of folate into the cell like 
potocytosis and GPI-anchored protein enriched endocytic compartments (GEEC’s).  
Folate-conjugates bind falate receptor with high affinity and are subsequently internalized 
into endosomes and that can reduce disulfied bonds. In the absence of any cleavable bond, the 
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attached conjugate will not release and will not be degraded. Within the endosome, the folate-
imaging agent conjugate is released from the folate receptor.22-24 (figure-2) 
Folate conjugate 
Folate can be coupled with different molecules like chemotherapeutic agents, protein 
toxins, immunotherapeuticsagents, antisense oligonucleotides, liposomes entrapped drug, 
polymeric drug carrier and imaging agents.25 Imaging agents can be conjugated to folic acid 
using variety of linkers and cleavable bonds without affecting the binding affinity of the folate 
moiety to the folate receptor. Peptides or carbon chain can be used as spacer depending upon size 
of imaging agent.26-27 The general scheme of folate-dye or drug conjugate is shown in figure-3.  
Folate base conjugates have very good penetration power due to its low molecular weight as 
compared to antibodies. Production cost of antibodies is very high which leads to higher cost for 
in vivo as well as in vitro diagnosis.28  
DylightTM 549 Meleimide 
DylightTM 549 Meleimide have absorption spectra ranging from 350 to 770 nm. The 
water solubility of the DylightTM 549 Meleimide allows  very high flour to protein ratio without 
precipitation during conjugation. It contain meleimide groups that react with free –SH groups at 
pH 6.5 to 7.5 and it form a stable thioether bond. At pH  7, the meleimide group of Dylight 549 is  
more reactive towards a free sulfhydry group than to an amine group. At pH 7.5 reactivity of 
meleimide groups towards primary amines increases and hydrolysis of meleimide group can 
occur. DylightTM 549 Meleimide is excited at 562 nm and emitted at 576 nm. It remains intensely 
fluorescent over a broad pH range from 4 to 9.29  
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Materials and method 
Material used for synthesis 
Synthesized Folate- Peptide (Folate-Asp-Arg-Asp-Asp-Cys-SH), DylightTM 549 
meleimide was supplied by Thermo Scientific, 99% DIPEA (N,N-Diisopropylethylamine) 
supplied by Aldrich chemicals, DMSO (Dimethylsulfoxide) supplied by fisher scientific. 
Synthesis of Folate-dylightTM 549 
1 mg DylightTM 549 meleimide was dissolved in 200 µl Dimethylsulfoxide. 0.002 gm 
synthesized Folate- Peptide (Folate-Asp-Arg-Asp-Asp-Cys-SH) added to the 90 µl above 
solution. Add 13 µl 99% DIPEA (N,N-Diisopropylethylamine) solution and mixed for 8 hours 
by magnetic stirer at room temperature. The product was purified by reverse phase HPLC and 
Analyzed by LC/MS. The synthesis of Folate-DylightTM 549 meleimide is showen in (figure-4)  
Instrumentation 
Experimental parameters for HPLC 
The analysis of synthesized product was done by HPLC (Hewlett Packard, serise1050 
with DAD) with YMC, HPLC column with particle size 6 µm and  dimension 4.6 x 150 mm. 
Purification was done by Rigel HPLC C18 (preparative column) with particle size 5 µm and 
column dimension 10 x 250 mm.                                                                                           
Solvent:  10 mM NH4HCO3 and ACN                                                                                              
Flow rate: 1 ml/min                                                                                                              
Detector:  DAD with scanning range 200-600                                                                       
Method:  BIOTINRH.M 
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Gradient method for folate-Dylight conjugates purification (HPLC) 
Time (min) % B 
0.00 1 
1.00 1 
20.0 99 
40.0 99 
41.0 99 
50.0 99 
52.0 1 
60.0 1 
 
Experimental parameters for LC/MS 
An analytical assessment of purified product was done by using Agilent 1100 series LC 
equipped with Agilent Technologies LC/MSD trap XCT on Agilent eclipse XDB C18 column 
(5µm, 4.6 x 150 mm)                                                                                                                                        
Solvent: Water and Methanol (Negative mode)                                                                                       
Flow rate: 0.5 ml/min                                                                                                                  
Nebulizer pressure: 40 psi                                                                                                                                
Dry temperature: 300 0  C                                                                                                                    
Scanning range: 300-1100 m/z                                                                                                         
Injection Volume: 10 µl of Folate-Dylight conjugates 
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Gradient method for folate-Dylight conjugates analysis (LC/MS) 
Time (min) % B 
0 30 
1 50 
2 70 
3 90 
 
Results and Discussion 
The synthesis method for Folate-DylightTM 549 was simple and quick. In this method, 
Folate-Peptide and commercially available DylightTM 549 conjugated via maleimide chemistry. 
The synthesis method was inexpensive and can be performed in small laboratories.The main 
advantage of this synthetic approach is that Folate-Peptide is very stable, stored for long period 
of time and may be useful for large scale synthesis. 
For the purification of Folate-DylightTM 549 conjugate was done by using reverse phase 
HPLC with BIOTINRH.M method developed by Dr. Henne. Total run time was 60 minutes 
because of better purification of conjugates from other impurities. The DAD signals were 
continuously observed at 280 nm to collect the component of interest. Before purification, 
analytical column was used to figure out the elution time for components of interest. For the 
analytical run, 30 µl injection of crude product was injected and analyzed. (Figure-5) There are 
three major peak observed at 1.5 min, 1.8 min and 2.2 min. Peak observed at 1.8 min was Folate-
DylightTM 549 conjugate and peaks observed at 1.5 min and 2.2 min were unreacted folate and 
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DylightTM 549 respectively according to the DAD absorption spectrum. Here main difficulty was 
that purification of component of interest because of retention time of each peak was too closer. 
Finally, started to play with parameters and made method fast by changing % B flow rate. 
After long trouble, each peak separated chromatogram observed. (Figure-6) Folate-DylightTM 
549 conjugate being separated and eluted at 13.6 min and fraction of that peak collected in 
LCMS vials for further analysis whereas unreacted folate and DylightTM 549 eluted at 9.2 min 
and 20.1 min respectively and fraction of that peak collected in LCMS vials for future reference.  
The analysis of Folate-DylightTM 549 conjugate was done by analytical LC/MS in 
negative mode on an Agilent Eclipsed XDB C18 column (5 µm, 4.6 ×150 mm). Figure-7 shows 
the chromatogram of purified Folate-DylightTM 549 conjugate with retention time 2.33 min. The 
sample was previously purified, so any other impurity peaks were not observed in 
chromatogram. The peak eluted at 2.33 min in chromatogram was confirmed by DAD absorption 
spectrum which was consistent with the intended compound. Figure-8 shows the DAD spectrum 
of Folate-DylightTM 549 conjugate that eluted at 2.33 min. The scanning range for DAD 
spectrum was 200-800 nm. DAD spectrum shows two absorbance maxima, one at 282 nm and 
other at 556 nm. Peak at 282 nm was due to presence of Folic acid and DylightTM 549 and a peak 
at 556 nm was due to DylightTM 549. This result indicates that injected sample contains both 
DylightTM 549 and folate. 
Figure-9 shows the mass spectrum of Folate-DylightTM 549 conjugate in negative mode. 
The scanning range of mass spectrum was 300-1100 m/z. The mass spectrum yields shows four 
major peaks at 396.6 m/z, 495.5 m/z, 660.9 m/z and 991.7 m/z. The molecular weight (M) of 
Folate-DylightTM 549 conjugate was 1986 g/mol. But, after several attempts we were not able to 
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get single charged molecular ion peak (M-H+). Instead of single charge molecular ion peak, we 
observed double charged ion peak, triple charged ion peak, four charged ion peak and five 
charged ion peak. A peak observed at 991.7 m/z is double charged molecular ion peak  (m/2z, 
M-2H+ ) which is corresponded to the molecular weight of Folate-DylightTM 549 conjugate after 
loss of two protons from the molecule. A peak observed at 660.9 m/z is triple charged molecular 
ion peak(m/3z, M-3H+ ) which is identical to the molecular weight of Folate-DylightTM 549 
conjugate after loss of three protons from the molecule. A peak observed at 495.5 m/z is four 
charged molecular ion peak(m/4z, M-4H+ ) which is corresponded to the molecular weight of 
Folate-DylightTM 549 conjugate after loss of four protons from the molecule. Moreover one more 
peak observed at 396.6 is five charged molecular ion peak(m/5z, M-5H+ ) which is corresponded 
to the molecular weight of Folate-DylightTM 549 conjugate after loss of five protons from the 
molecule. 
Although, it is not necessary to get single charge molecular ion peak for identification of 
compound. It is often occurs with large peptides. In this case, there are several possibilities for 
not getting single molecular ion peak. It may be due to high molecular weight of compound, so 
ionization of large species is difficult. Moreover, it also may be due to compound contains five 
COOH groups and its ionization occurs rapidly. 
Finally, there are four more consistent peak observed in mass spectrum at 1003.3 m/z, 
667.9 m/z, 500.9 m/z and 400.9 m/z which is due to formation of sodium adduct (addition of 
sodium and loss of hydrogen). According to this mass spectrum, the consistency of double, 
triple, four and five charged ion peaks and consistency of sodium adduct (pattern of parent ion) 
confirmed the identity of Folate-DylightTM 549 conjugate was present.     
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Conclusion 
Folate-DylightTM 549 was successfully synthesized by very simple, inexpensive and safe 
method. The whole synthesis method can be performed in small laboratories with minimum 
resources and small quantity of reagents required. The synthesized Folate-DylightTM 549 
conjugate was successfully purified by HPLC. The purified Folate-DylightTM 549 conjugate was 
successfully evaluated and confirmed by LC-MS and LC-DAD. Moreover, Sodium adduct gave 
additional confirmation of the compound. 
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Figure-3: General scheme for folate-Dye conjugates 
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Figure-4: Synthetic scheme of Folate-DylightTM 549 conjugates synthesis 
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Figure-5: Chromatogram of crude Folate-DylightTM 549 conjugates at 280 nm in HPLC 
 
 
 
 
 
 
 
22	  
	  
 
 
 
 
 
 
Figure-6: Chromatogram of crude Folate-DylightTM 549 conjugates at 280 nm in HPLC (after 
method developed) 
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Figure-7: Chromatogram of purified Folate-DylightTM 549 conjugates at 280 nm (LC-DAD) 
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Figure-8: DAD spectrum of Folate-DylightTM 549 conjugates (LC-DAD) 
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 Expected (m/z) Found (m/z) 
Double charge molecular ion peak 992 991.7 
Triple charge molecular ion peak 661 660.9 
Four charge molecular ion peak 495.5 495.5 
Five charge molecular ion peak 396.2 396.6 
 
 
Figure-9: Mass spectrum of Folate-DylightTM 549 conjugates in negative ion mode (LC/MS) 
